Some Data, Please
By Genome Web,
Genome Web
| 01. 08. 2014
A company and its former subsidiary have settled with the US Federal Trade Commission, which said the companies' advertising claims regarding their genetically tailored nutritional supplements and skincare products were deceptive.
In their marketing material, GeneLink and Foru said that their customized products - customers sent in cheek swabs for genetic analysis - could help overcome genetic shortcomings, according to the FTC. For instance, included testimonials said that the supplements could treat diseases such as diabetes, heart disease, and insomnia, and that the effectiveness of the skin repair serum was scientifically proven. In addition, FTC says the companies did not have appropriate safeguards to ensure the privacy of customers' genetic information, Social Security numbers, and bank account information.
As part of the proposed settlement, the companies would be barred from making claims that their products prevent, treat, or reduce the risk of any disease unless it is true and backed up by at least two well-controlled studies. In addition, any claim saying that a product treats or prevents a disease in someone with certain genetic variation has to be...
Related Articles
By Annika Inampudi, Science | 07.10.2025
Before a baby in the United States reaches a few days old, doctors will run biochemical tests on a few drops of their blood to catch certain genetic diseases that need immediate care to prevent brain damage or other serious...
By Geoffrey A. Fowler, The Washington Post | 07.17.2025
Nearly 2 million people protected their privacy by deleting their DNA from 23andMe after it declared bankruptcy in March. Now it’s back with the same person in charge — and I still don’t trust it.
Nor do the attorneys general...
By Elizabeth Dwoskin and Yeganeh Torbati, The Washington Post | 07.16.2025
A group of well-heeled, 30-something women sat down to dinner last spring at a table set with pregnancy-friendly mocktails and orchids, ready to hear a talk about how to optimize their offspring.
Noor Siddiqui, the founder of an embryo-screening start-up...
By Suzanne O'Sullivan, New Scientist | 07.09.2025
Rare diseases are often hard to spot. They can evade detection until irreversible organ damage or disability has already set in. Last month, in the hope of preventing just this type of harm, the UK’s health secretary, Wes Streeting, announced...